FRM
ZBIO

Fox Run Management’s Zenas BioPharma ZBIO Stock Holding History

Fox Run Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Buy
+13,331
New +$299K 0.04% 696

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Fox Run Management's ZBIO Position: Q1 2026 in Review

Fox Run Management opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 13,331 shares worth $243K. The stake represents 0.04% of the portfolio and ranks #696 among its holdings.

139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Fox Run Management held 13,331 shares of Zenas BioPharma worth $243K as of Q1 2026.
  • Zenas BioPharma was a new Fox Run Management position in Q1 2026.
  • Zenas BioPharma made up 0.04% of Fox Run Management's portfolio in Q1 2026, its #696 holding.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.